-
1
-
-
2142714017
-
Monoclonal antibodies as therapeutic agents for cancer
-
PMID:15120666
-
Harris M. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol 2004; 5:292-302; PMID:15120666; http://dx.doi.org/10.1016/S1470-2045(04) 01467-6.
-
(2004)
Lancet Oncol
, vol.5
, pp. 292-302
-
-
Harris, M.1
-
2
-
-
84859140047
-
Improving treatment of HER2-positive cancers: Opportunities and challenges
-
doi:10.1126/scitranslmed.3001539
-
Stern HM. Improving treatment of HER2-positive cancers: opportunities and challenges. Sci Transl Med 2012; 4:127rv2. doi:10.1126/scitranslmed.3001539.
-
(2012)
Sci Transl Med
, vol.4
-
-
Stern, H.M.1
-
3
-
-
52949085848
-
Ertumaxomab: A trifunctional antibody for breast cancer treatment
-
PMID:18808314
-
Kiewe P, Thiel E. Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 2008; 17:1553-8; PMID:18808314; http://dx.doi.org/10.1517/13543784.17.10.1553.
-
(2008)
Expert Opin Investig Drugs
, vol.17
, pp. 1553-1558
-
-
Kiewe, P.1
Thiel, E.2
-
4
-
-
33744803712
-
Phase I trial of the trifunctional anti- HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer
-
PMID:16707606
-
Kiewe P, Hasmüller S, Kahlert S, Heinrigs M, Rack B, Marmé A, et al. Phase I trial of the trifunctional anti- HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res 2006; 12:3085-91; PMID:16707606; http://dx.doi.org/10.1158/1078-0432.CCR-05-2436.
-
(2006)
Clin Cancer Res
, vol.12
, pp. 3085-3091
-
-
Kiewe, P.1
Hasmüller, S.2
Kahlert, S.3
Heinrigs, M.4
Rack, B.5
Marmé, A.6
-
5
-
-
84873087647
-
Phase II study of single agent trifunctional antibody ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 low expressing hormone-refractory advanced breast cancer patients (ABC)
-
Cardoso F, Dirix L, Conte PF, Semiglazov V, de Placido S, Jaeger M, et al. Phase II study of single agent trifunctional antibody ertumaxomab (Anti-HER-2 & Anti-CD3) in HER-2 low expressing hormone-refractory advanced breast cancer patients (ABC). San Antonio Breast Cancer Symposium 2010; P3-14-21.
-
(2010)
San Antonio Breast Cancer Symposium
-
-
Cardoso, F.1
Dirix, L.2
Conte, P.F.3
Semiglazov, V.4
De Placido, S.5
Jaeger, M.6
-
6
-
-
66249126868
-
The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2
-
PMID:19435924
-
Jäger M, Schoberth A, Ruf P, Hess J, Lindhofer H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res 2009; 69:4270-6; PMID:19435924; http://dx.doi.org/10.1158/0008-5472.CAN-08-2861.
-
(2009)
Cancer Res
, vol.69
, pp. 4270-4276
-
-
Jäger, M.1
Schoberth, A.2
Ruf, P.3
Hess, J.4
Lindhofer, H.5
-
7
-
-
0034051390
-
The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells
-
PMID:10901380
-
Zeidler R, Mysliwietz J, Csánady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000; 83:261-6; PMID:10901380.
-
(2000)
Br J Cancer
, vol.83
, pp. 261-266
-
-
Zeidler, R.1
Mysliwietz, J.2
Csánady, M.3
Walz, A.4
Ziegler, I.5
Schmitt, B.6
-
8
-
-
60649122009
-
Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis
-
PMID:19216794
-
Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM. Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 2009; 28:18; PMID:19216794; http://dx.doi.org/10.1186/1756-9966-28-18.
-
(2009)
J Exp Clin Cancer Res
, vol.28
, pp. 18
-
-
Ströhlein, M.A.1
Siegel, R.2
Jäger, M.3
Lindhofer, H.4
Jauch, K.W.5
Heiss, M.M.6
-
9
-
-
0032101894
-
EGF-induced redistribution of erbB2 on breast tumor cells: Flow and image cytometric energy transfer measurements
-
PMID:9627225
-
Nagy P, Bene L, Balázs M, Hyun WC, Lockett SJ, Chiang NY, et al. EGF-induced redistribution of erbB2 on breast tumor cells: flow and image cytometric energy transfer measurements. Cytometry 1998; 32:120- 31; PMID:9627225; http://dx.doi.org/10.1002/(SICI)1097-0320(19980601)32:2〈120:: AIDCYTO7〉3.0.CO;2-P.
-
(1998)
Cytometry
, vol.32
, pp. 120-131
-
-
Nagy, P.1
Bene, L.2
Balázs, M.3
Hyun, W.C.4
Lockett, S.J.5
Chiang, N.Y.6
-
10
-
-
47249112974
-
Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis
-
PMID:18596360
-
Diermeier-Daucher S, Hasmann M, Brockhoff G. Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basis. Ann N Y Acad Sci 2008; 1130:280-6; PMID:18596360; http://dx.doi.org/10.1196/annals.1430.003.
-
(2008)
Ann N Y Acad Sci
, vol.1130
, pp. 280-286
-
-
Diermeier-Daucher, S.1
Hasmann, M.2
Brockhoff, G.3
-
11
-
-
0035256698
-
Untangling the Erb Bsignalling network
-
PMID:11252954
-
Yarden Y, Sliwkowski MX. Untangling the Erb Bsignalling network. Nat Rev Mol Cell Biol 2001; 2:127-37; PMID:11252954; http://dx.doi.org/10.1038/35052073.
-
(2001)
Nat Rev Mol Cell Biol
, vol.2
, pp. 127-137
-
-
Yarden, Y.1
Sliwkowski, M.X.2
-
12
-
-
83655196673
-
Novel monoclonal antibodies for cancer treatment: The trifunctional antibody catumaxomab (removab)
-
PMID:21716847
-
Seimetz D. Novel monoclonal antibodies for cancer treatment: the trifunctional antibody catumaxomab (removab). J Cancer 2011; 2:309-16; PMID:21716847; http://dx.doi.org/10.7150/jca.2.309.
-
(2011)
J Cancer
, vol.2
, pp. 309-316
-
-
Seimetz, D.1
-
13
-
-
77953665930
-
Structural and functional characterization of the trifunctional antibody catumaxomab
-
PMID:20418662
-
Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2010; 2:309-19; PMID:20418662; http://dx.doi.org/10.4161/mabs. 2.3.11791.
-
(2010)
MAbs
, vol.2
, pp. 309-319
-
-
Chelius, D.1
Ruf, P.2
Gruber, P.3
Plöscher, M.4
Liedtke, R.5
Gansberger, E.6
-
14
-
-
84859409756
-
Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3
-
PMID:22248472
-
McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11- 0820.
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 582-593
-
-
McDonagh, C.F.1
Huhalov, A.2
Harms, B.D.3
Adams, S.4
Paragas, V.5
Oyama, S.6
-
15
-
-
84859802154
-
Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose
-
PMID:22203367
-
Kamath AV, Lu D, Gupta P, Jin D, Xiang H, Wong A, et al. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 2012; 69:1063-9; PMID:22203367; http://dx.doi.org/10.1007/ s00280-011-1806-6.
-
(2012)
Cancer Chemother Pharmacol
, vol.69
, pp. 1063-1069
-
-
Kamath, A.V.1
Lu, D.2
Gupta, P.3
Jin, D.4
Xiang, H.5
Wong, A.6
-
16
-
-
84855297353
-
Efficacy and safety of neoadjuvantpertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): A randomisedmulticentre, openlabel, phase 2 trial
-
PMID:22153890
-
Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvantpertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomisedmulticentre, openlabel, phase 2 trial. Lancet Oncol 2012; 13:25-32; PMID:22153890; http://dx.doi.org/10.1016/S1470-2045(11)70336-9.
-
(2012)
Lancet Oncol
, vol.13
, pp. 25-32
-
-
Gianni, L.1
Pienkowski, T.2
Im, Y.H.3
Roman, L.4
Tseng, L.M.5
Liu, M.C.6
-
17
-
-
84862914692
-
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
-
CLEOPATRA Study Group. PMID:22149875
-
Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, et al.; CLEOPATRA Study Group. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109-19; PMID:22149875; http://dx.doi.org/10.1056/NEJMoa1113216.
-
(2012)
N Engl J Med
, vol.366
, pp. 109-119
-
-
Baselga, J.1
Cortés, J.2
Kim, S.B.3
Im, S.A.4
Hegg, R.5
Im, Y.H.6
-
18
-
-
79952276644
-
CLEOPATRA: A phase III evaluation of pertuzumab and trastuzumab for HER2- Positive metastatic breast cancer
-
PMID:21147694
-
Baselga J, Swain SM. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2- positive metastatic breast cancer. Clin Breast Cancer 2010; 10:489-91; PMID:21147694; http://dx.doi.org/10.3816/CBC.2010.n.065.
-
(2010)
Clin Breast Cancer
, vol.10
, pp. 489-491
-
-
Baselga, J.1
Swain, S.M.2
-
19
-
-
84856223809
-
Dual HER2-targeted approaches in HER2-positive breast cancer
-
PMID:21956210
-
Ahn ER, Vogel CL. Dual HER2-targeted approaches in HER2-positive breast cancer. Breast Cancer Res Treat 2012; 131:371-83; PMID:21956210; http://dx.doi.org/10.1007/s10549-011-1781-y.
-
(2012)
Breast Cancer Res Treat
, vol.131
, pp. 371-383
-
-
Ahn, E.R.1
Vogel, C.L.2
-
20
-
-
73649149433
-
Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models
-
PMID:19934333
-
Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009; 69:9330-6; PMID:19934333; http://dx.doi.org/10.1158/0008-5472.CAN-08-4597.
-
(2009)
Cancer Res
, vol.69
, pp. 9330-9336
-
-
Scheuer, W.1
Friess, T.2
Burtscher, H.3
Bossenmaier, B.4
Endl, J.5
Hasmann, M.6
-
21
-
-
65349101151
-
Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941
-
PMID:19411071
-
Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009; 15:429-40; PMID:19411071; http://dx.doi.org/10.1016/j.ccr.2009.03.020.
-
(2009)
Cancer Cell
, vol.15
, pp. 429-440
-
-
Junttila, T.T.1
Akita, R.W.2
Parsons, K.3
Fields, C.4
Lewis Phillips, G.D.5
Friedman, L.S.6
-
22
-
-
19044380618
-
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
-
PMID:12204533
-
Agus DB, Akita RW, Fox WD, Lewis GD, Higgins B, Pisacane PI, et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2:127-37; PMID:12204533; http://dx.doi.org/10.1016/ S1535-6108(02)00097-1.
-
(2002)
Cancer Cell
, vol.2
, pp. 127-137
-
-
Agus, D.B.1
Akita, R.W.2
Fox, W.D.3
Lewis, G.D.4
Higgins, B.5
Pisacane, P.I.6
-
23
-
-
1942474587
-
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
-
PMID:15059883
-
Nahta R, Hung MC, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 2004; 64:2343-6; PMID:15059883; http://dx.doi.org/10.1158/0008-5472. CAN-03-3856.
-
(2004)
Cancer Res
, vol.64
, pp. 2343-2346
-
-
Nahta, R.1
Hung, M.C.2
Esteva, F.J.3
-
24
-
-
0030959114
-
A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors
-
PMID:9160890
-
Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997; 14:2099-109; PMID:9160890; http://dx.doi.org/10.1038/sj.onc.1201029.
-
(1997)
Oncogene
, vol.14
, pp. 2099-2109
-
-
Klapper, L.N.1
Vaisman, N.2
Hurwitz, E.3
Pinkas-Kramarski, R.4
Yarden, Y.5
Sela, M.6
-
25
-
-
0037434791
-
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
-
PMID:12610629
-
Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756- 60; PMID:12610629; http://dx.doi.org/10. 1038/nature01392.
-
(2003)
Nature
, vol.421
, pp. 756-760
-
-
Cho, H.S.1
Mason, K.2
Ramyar, K.X.3
Stanley, A.M.4
Gabelli, S.B.5
Denney Jr., D.W.6
-
26
-
-
1842605531
-
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
-
PMID:15093539
-
Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28; PMID:15093539; http://dx.doi.org/10.1016/S1535- 6108(04)00083-2.
-
(2004)
Cancer Cell
, vol.5
, pp. 317-328
-
-
Franklin, M.C.1
Carey, K.D.2
Vajdos, F.F.3
Leahy, D.J.4
De Vos, A.M.5
Sliwkowski, M.X.6
-
27
-
-
14644392200
-
Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation
-
PMID:15748904
-
Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 2005; 304:604-19; PMID:15748904; http://dx.doi.org/10.1016/j.yexcr.2004.12.008.
-
(2005)
Exp Cell Res
, vol.304
, pp. 604-619
-
-
Diermeier, S.1
Horváth, G.2
Knuechel-Clarke, R.3
Hofstaedter, F.4
Szöllosi, J.5
Brockhoff, G.6
-
28
-
-
0026360077
-
p185HER2 signal transduction in breast cancer cells
-
PMID:1677643
-
Scott GK, Dodson JM, Montgomery PA, Johnson RM, Sarup JC, Wong WL, et al. p185HER2 signal transduction in breast cancer cells. J Biol Chem 1991; 266:14300-5; PMID:1677643.
-
(1991)
J Biol Chem
, vol.266
, pp. 14300-14305
-
-
Scott, G.K.1
Dodson, J.M.2
Montgomery, P.A.3
Johnson, R.M.4
Sarup, J.C.5
Wong, W.L.6
-
29
-
-
33646739287
-
Effects of HER2-binding affibody molecules on intracellular signaling pathways
-
PMID:16651854
-
Ekerljung L, Steffen AC, Carlsson J, Lennartsson J. Effects of HER2-binding affibody molecules on intracellular signaling pathways. Tumour Biol 2006; 27:201-10; PMID:16651854; http://dx.doi.org/10.1159/000093023.
-
(2006)
Tumour Biol
, vol.27
, pp. 201-210
-
-
Ekerljung, L.1
Steffen, A.C.2
Carlsson, J.3
Lennartsson, J.4
-
30
-
-
0033392493
-
Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1
-
PMID:10635327
-
Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999; 4:1029-40; PMID:10635327; http://dx.doi.org/10.1016/S1097-2765(00)80231-2.
-
(1999)
Mol Cell
, vol.4
, pp. 1029-1040
-
-
Levkowitz, G.1
Waterman, H.2
Ettenberg, S.A.3
Katz, M.4
Tsygankov, A.Y.5
Alroy, I.6
-
31
-
-
0032512841
-
Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation
-
PMID:9461599
-
Zrihan-Licht S, Deng B, Yarden Y, McShan G, Keydar I, Avraham H. Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation. J Biol Chem 1998; 273:4065-72; PMID:9461599; http://dx.doi.org/ 10.1074/jbc.273.7.4065.
-
(1998)
J Biol Chem
, vol.273
, pp. 4065-4072
-
-
Zrihan-Licht, S.1
Deng, B.2
Yarden, Y.3
McShan, G.4
Keydar, I.5
Avraham, H.6
-
32
-
-
0030794283
-
Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation
-
PMID:9271418
-
Dankort DL, Wang Z, Blackmore V, Moran MF, Muller WJ. Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation. Mol Cell Biol 1997; 17:5410-25; PMID:9271418.
-
(1997)
Mol Cell Biol
, vol.17
, pp. 5410-5425
-
-
Dankort, D.L.1
Wang, Z.2
Blackmore, V.3
Moran, M.F.4
Muller, W.J.5
-
33
-
-
33745585792
-
Phosphoproteomic analysis of Her2/neu signaling and inhibition
-
PMID:16785428
-
Bose R, Molina H, Patterson AS, Bitok JK, Periaswamy B, Bader JS, et al. Phosphoproteomic analysis of Her2/neu signaling and inhibition. Proc Natl Acad Sci U S A 2006; 103:9773-8; PMID:16785428; http://dx.doi.org/10.1073/pnas. 0603948103.
-
(2006)
Proc Natl Acad Sci U S A
, vol.103
, pp. 9773-9778
-
-
Bose, R.1
Molina, H.2
Patterson, A.S.3
Bitok, J.K.4
Periaswamy, B.5
Bader, J.S.6
-
34
-
-
0032482368
-
Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential
-
PMID:9671404
-
Zhang HT, O'Rourke DM, Zhao H, Murali R, Mikami Y, Davis JG, et al. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential. Oncogene 1998; 16:2835-42; PMID:9671404; http://dx.doi.org/10.1038/sj.onc.1201820.
-
(1998)
Oncogene
, vol.16
, pp. 2835-2842
-
-
Zhang, H.T.1
O'Rourke, D.M.2
Zhao, H.3
Murali, R.4
Mikami, Y.5
Davis, J.G.6
-
35
-
-
33845804718
-
Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity
-
PMID:17030621
-
Xu W, Yuan X, Beebe K, Xiang Z, Neckers L. Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity. Mol Cell Biol 2007; 27:220-8; PMID:17030621; http://dx.doi.org/10.1128/MCB.00899-06.
-
(2007)
Mol Cell Biol
, vol.27
, pp. 220-228
-
-
Xu, W.1
Yuan, X.2
Beebe, K.3
Xiang, Z.4
Neckers, L.5
-
36
-
-
0032422140
-
Pharmacokinetics and biodistribution of genetically-engineered antibodies
-
PMID:9973838
-
Colcher D, Pavlinkova G, Beresford G, Booth BJ, Choudhury A, Batra SK. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q J Nucl Med 1998; 42:225-41; PMID:9973838.
-
(1998)
Q J Nucl Med
, vol.42
, pp. 225-241
-
-
Colcher, D.1
Pavlinkova, G.2
Beresford, G.3
Booth, B.J.4
Choudhury, A.5
Batra, S.K.6
-
37
-
-
79952741743
-
Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors
-
PMID:21406401
-
Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, et al. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res 2011; 71:2250-9; PMID:21406401; http://dx.doi.org/10.1158/0008-5472.CAN-10-2277.
-
(2011)
Cancer Res
, vol.71
, pp. 2250-2259
-
-
Rudnick, S.I.1
Lou, J.2
Shaller, C.C.3
Tang, Y.4
Klein-Szanto, A.J.5
Weiner, L.M.6
-
38
-
-
0032895235
-
Trastuzumab, a recombinant DNAderived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer
-
PMID:10211534
-
Goldenberg MM. Trastuzumab, a recombinant DNAderived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21:309-18; PMID:10211534; http://dx.doi.org/10.1016/S0149-2918(00) 88288-0.
-
(1999)
Clin Ther
, vol.21
, pp. 309-318
-
-
Goldenberg, M.M.1
-
39
-
-
0033953634
-
Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo
-
PMID:10657127
-
Park BW, Zhang HT, Wu C, Berezov A, Zhang X, Dua R, et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat Biotechnol 2000; 18:194-8; PMID:10657127; http://dx.doi.org/10.1038/72651.
-
(2000)
Nat Biotechnol
, vol.18
, pp. 194-198
-
-
Park, B.W.1
Zhang, H.T.2
Wu, C.3
Berezov, A.4
Zhang, X.5
Dua, R.6
-
40
-
-
84856034032
-
Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment
-
PMID:22126733
-
Schroeder P, Lindemann C, Dettmar K, Brieger J, Gosepath J, Pogorzelski B, et al. Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clin Transl Oncol 2011; 13:889-98; PMID:22126733; http://dx.doi.org/10.1007/s12094-011-0751-5.
-
(2011)
Clin Transl Oncol
, vol.13
, pp. 889-898
-
-
Schroeder, P.1
Lindemann, C.2
Dettmar, K.3
Brieger, J.4
Gosepath, J.5
Pogorzelski, B.6
-
41
-
-
0035889129
-
Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody
-
PMID:11588051
-
Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98:2526-34; PMID:11588051; http://dx.doi.org/10.1182/blood.V98.8.2526.
-
(2001)
Blood
, vol.98
, pp. 2526-2534
-
-
Ruf, P.1
Lindhofer, H.2
-
42
-
-
47149094444
-
Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctionalbispecific antibody
-
PMID:18495330
-
Morecki S, Lindhofer H, Yacovlev E, Gelfand Y, Ruf P, Slavin S. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctionalbispecific antibody. Exp Hematol 2008; 36:997-1003; PMID:18495330; http://dx.doi.org/10.1016/j.exphem.2008.03.005.
-
(2008)
Exp Hematol
, vol.36
, pp. 997-1003
-
-
Morecki, S.1
Lindhofer, H.2
Yacovlev, E.3
Gelfand, Y.4
Ruf, P.5
Slavin, S.6
-
43
-
-
34447336165
-
Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation
-
PMID:17635517
-
Brockhoff G, Heckel B, Schmidt-Bruecken E, Plander M, Hofstaedter F, Vollmann A, et al. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif 2007; 40:488-507; PMID:17635517; http://dx.doi.org/10.1111/j.1365-2184.2007.00449.x.
-
(2007)
Cell Prolif
, vol.40
, pp. 488-507
-
-
Brockhoff, G.1
Heckel, B.2
Schmidt-Bruecken, E.3
Plander, M.4
Hofstaedter, F.5
Vollmann, A.6
-
44
-
-
0021273333
-
Flow cytometric measurement of fluorescence resonance energy transfer on cell surfaces. Quantitative evaluation of the transfer efficiency on a cell-by-cell basis
-
PMID:6428482
-
Trón L, Szöllósi J, Damjanovich S, Helliwell SH, Arndt-Jovin DJ, Jovin TM. Flow cytometric measurement of fluorescence resonance energy transfer on cell surfaces. Quantitative evaluation of the transfer efficiency on a cell-by-cell basis. Biophys J 1984; 45:939- 46; PMID:6428482; http://dx.doi.org/10.1016/S0006-3495(84)84240-X.
-
(1984)
Biophys J
, vol.45
, pp. 939-946
-
-
Trón, L.1
Szöllósi, J.2
Damjanovich, S.3
Helliwell, S.H.4
Arndt-Jovin, D.J.5
Jovin, T.M.6
-
45
-
-
3242784810
-
Computer program for determining fluorescence resonance energy transfer efficiency from flow cytometric data on a cell-by-cell basis
-
PMID:15265619
-
Szentesi G, Horváth G, Bori I, Vámosi G, Szöllosi J, Gáspár R, et al. Computer program for determining fluorescence resonance energy transfer efficiency from flow cytometric data on a cell-by-cell basis. Comput Methods Programs Biomed 2004; 75:201-11; PMID:15265619; http://dx.doi.org/10.1016/j.cmpb.2004.02.004.
-
(2004)
Comput Methods Programs Biomed
, vol.75
, pp. 201-211
-
-
Szentesi, G.1
Horváth, G.2
Bori, I.3
Vámosi, G.4
Szöllosi, J.5
Gáspár, R.6
-
46
-
-
44149098849
-
Cytogenetic analysis of HER1/ EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
-
PMID:18182100
-
Sassen A, Rochon J, Wild P, Hartmann A, Hofstaedter F, Schwarz S, et al. Cytogenetic analysis of HER1/ EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res 2008; 10:R2; PMID:18182100; http://dx.doi.org/10. 1186/bcr1843.
-
(2008)
Breast Cancer Res
, vol.10
-
-
Sassen, A.1
Rochon, J.2
Wild, P.3
Hartmann, A.4
Hofstaedter, F.5
Schwarz, S.6
|